You just read:

Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

News provided by

Sangamo Therapeutics, Inc.

Sep 05, 2018, 08:14 ET